FDA Cleared · Coming October 2026
Major regulatory hurdles cleared. Dispensing expected October 2026.
BPC-157, TB-500, KPV, MOTS-C, and Semax have cleared the primary FDA regulatory hurdles. Formal dispensing authorisation is expected around October 2026. WellSpry will begin prescribing these immediately upon availability — test now so your baseline is ready.
BPC-157
Body Protection Compound · 15-Amino Acid
Coming Oct 2026
Biomarker Trigger
Gut microbiome score <5 · hs-CRP elevated · GI side effects on GLP-1
Expected Use
Gut lining repair, barrier integrity, tissue repair. Oral capsule for gut applications; subcutaneous injection for systemic use. The most anticipated addition to the WellSpry stack.
Test Now — Be Ready
Core Metabolic Panel · $169
AST · ALT · BUN · Creatinine
TB-500
Thymosin Beta-4 Fragment
Coming Oct 2026
Biomarker Trigger
Elevated hs-CRP post-exercise · Joint/tendon issues reported · Active patients
Expected Use
Tissue regeneration, muscle repair, flexibility. Particularly valuable for patients training hard to preserve lean mass during GLP-1 therapy.
Test Now — Be Ready
Complete Hormone Panel · $249
hs-CRP · Free Testosterone
KPV
Lys-Pro-Val · Alpha-MSH Fragment
Coming Oct 2026
Biomarker Trigger
Gut microbiome score <4 · Elevated calprotectin · Gut-dominant inflammation
Expected Use
Anti-inflammatory gut support via MC1R signalling. Small size allows oral delivery. Typically paired with BPC-157 as a combined gut repair stack.
Test Now — Be Ready
Core Metabolic Panel · $169
AST · ALT · BUN
MOTS-C
Mitochondrial-Derived Peptide
Coming Oct 2026
Biomarker Trigger
Fat loss plateau · Poor exercise tolerance · HOMA-IR >2.5 despite adherence
Expected Use
Mitochondrial metabolic regulation via AMPK signalling. Addresses cellular energy dysfunction as the root cause of fat loss plateaus that persist despite dietary adherence.
Test Now — Be Ready
Core Metabolic Panel · $169
Triglycerides · LDL · HDL
Semax
ACTH 4-10 Analogue · Neuropeptide
Coming Oct 2026
Biomarker Trigger
Brain fog reported · hs-CRP elevated · Cortisol dysregulation pattern
Expected Use
Stimulates BDNF, enhances dopaminergic signalling, modulates cortisol. Addresses brain fog driven by gut-brain axis dysfunction. Intranasal administration for highest bioavailability.
Test Now — Be Ready
Complete Hormone Panel · $249
hs-CRP · Albumin · Cortisol AM
Still Pending — Formal FDA Publication
Announced for reclassification February 27, 2026. Formal Federal Register publication not yet issued. WellSpry monitors the Federal Register daily.
AOD-9604
Anti-Obesity Drug Fragment · hGH 177-191
Pending
Biomarker Trigger
Elevated fasting insulin · HOMA-IR >2.5 · Fat loss plateau despite GLP-1
Expected Use
Targets fat metabolism fragment of hGH without affecting blood sugar or growth. Can be used alongside or instead of GLP-1 for metabolic patients.
Order Ahead — Test Now
Core Metabolic Panel · $169
Triglycerides · LDL · HDL · TSH
Emideltide (DSIP)
Delta Sleep-Inducing Peptide
Pending
Biomarker Trigger
Elevated AM cortisol · Low testosterone secondary to sleep disruption
Expected Use
Sleep architecture support. Upstream fix for cortisol-driven fat resistance and hormone recovery blockage.
Order Ahead — Test Now
Complete Hormone Panel · $249
Total Testosterone · hs-TSH
Epitalon
Epithalamin · Tetrapeptide
Pending
Biomarker Trigger
Elevated biological age delta · Longevity track patients · 50+
Expected Use
Longevity and telomere support. Introduced alongside NAD+ at month 4 for patients whose biological age gap exceeds 5 years.
Order Ahead — Test Now
Complete Hormone Panel · $249
Albumin · Cholesterol · Lipids
GHK-Cu Injectable
Copper Peptide · Injectable Form
Pending
Biomarker Trigger
Skin assessment at month 2 · Rapid fat loss rate >2lbs/week
Expected Use
Systemic tissue repair. Distinct from WellSpry Skin topical GHK-Cu. Injectable form for patients with significant soft tissue changes or on full longevity track.
Order Ahead — Test Now
Core Metabolic Panel · $169
AST · ALT · Metabolic baseline
Kisspeptin-10
KiSS-1 Derived Peptide · Reproductive Axis
Pending
Biomarker Trigger
Low LH · Low FSH · Hormones segment · Perimenopausal or secondary hypogonadism
Expected Use
Hormone cascade regulation. For patients where LH is low and the upstream signal — not the gonads — is the problem.
Order Ahead — Test Now
Complete Hormone Panel · $249
LH · FSH · Total Testosterone · Estradiol
Thymosin Alpha-1
Immune Modulating Peptide · 28-Amino Acid
Pending
Biomarker Trigger
Depressed NK markers · Frequent illness · Elevated biological age · Cancer history
Expected Use
Strongest clinical evidence of any peptide on the list. Approved in 35+ countries. For patients whose immune markers show senescence.
Order Ahead — Test Now
Complete Hormone Panel · $249
hs-CRP · Albumin
FDA Formal Review · February 2027
The next wave. FDA review scheduled for February 2027.
LL-37, GHK-Cu, Dihexa acetate, Melanotan II, and PEG-MGF are lined up for formal FDA review by February 2027. Each has a distinct clinical application — antimicrobial defence, collagen repair, neural synaptogenesis, melanocortin signalling, and satellite cell activation. Test now to have your baseline documented before prescribing opens.
LL-37
Human Cathelicidin Antimicrobial Peptide · Host-Defence
Review Feb 2027
Biomarker Trigger
Recurrent infections · hs-CRP elevated · Low albumin · Gut-barrier compromise
Clinical Application
Innate immune modulation via TLR pathway, antimicrobial defence, and mucosal barrier support. The only endogenous human cathelicidin — produced in gut lining, lung, and skin.
Get Your Baseline — Test Now
Core Metabolic Panel · $169
hs-CRP · Albumin · AST · ALT
GHK-Cu
Glycyl-L-histidyl-L-lysine Copper · Tissue Repair
Review Feb 2027
Biomarker Trigger
Elevated hs-CRP · Low albumin · Significant skin changes · Collagen compromise
Clinical Application
Collagen synthesis stimulation, wound repair, and systemic anti-inflammation via NFkB pathway. GHK-Cu transport is albumin-dependent — albumin baseline determines bioavailability.
Get Your Baseline — Test Now
Core Metabolic Panel · $169
Albumin · hs-CRP · AST · ALT
Dihexa Acetate
HGF/Met Receptor · BDNF Potentiator · Neural Repair
Review Feb 2027
Biomarker Trigger
Brain fog reported · hs-CRP elevated · Low free testosterone · BDNF impairment suspected
Clinical Application
HGF mimetic that potentiates BDNF activity and stimulates synaptogenesis. Indicated when BDNF impairment is structural — distinct from Semax (cortisol-driven). Frequently co-prescribed with Semax.
Get Your Baseline — Test Now
Complete Hormone Panel · $249
hs-CRP · Free Testosterone · Albumin · Lipids
Melanotan II
Synthetic Melanocortin Receptor Agonist · MC1R–MC5R
Review Feb 2027
Biomarker Trigger
Photoprotection · Hypoactive sexual desire · Metabolic rate support during caloric restriction
Clinical Application
MC4R central agonist — photoprotection via MC1R, libido via hypothalamic MC4R, and metabolic rate modulation. Clinical indication determines dose and protocol.
Get Your Baseline — Test Now
Complete Hormone Panel · $249
Total Testosterone · hs-TSH · hs-CRP · Lipids
PEG-MGF
PEGylated Mechano Growth Factor · IGF-1 Splice Variant
Review Feb 2027
Biomarker Trigger
Poor muscle repair post-exercise · Elevated hs-CRP · Satellite cell dysfunction suspected
Clinical Application
Activates muscle satellite cells (stem cells) for myofibre repair, independent of systemic IGF-1. PEGylation extends half-life for practical dosing. Often combined with TB-500.
Get Your Baseline — Test Now
Complete Hormone Panel · $249
hs-CRP · Free Testosterone · Albumin · Lipids
Longevity Protocols
Beyond peptides — protocols that work alongside them.
WellSpry integrates NAD+ and other evidence-based longevity protocols with biomarker-driven prescribing. Every protocol is physician-ordered and monitored by lab results.
Available Now
NAD+
Nicotinamide Adenine Dinucleotide · IV · IM · Oral Precursors (NMN / NR)
IV from $249/session · Oral NMN/NR via supplement protocol
Biomarker Trigger
Biological age delta >5 years · HbA1c elevated · HOMA-IR >2.5 · Fatigue / cognitive decline · Longevity track patients 45+
Mechanism
NAD+ is the coenzyme that powers cellular energy production (ATP via Krebs cycle) and DNA repair (PARP enzymes). Levels decline ~50% by age 60. Replenishment activates sirtuins (SIRT1/3), improves mitochondrial function, reduces systemic inflammation, and improves insulin sensitivity. IV NAD+ provides rapid repletion; oral NMN or NR maintains levels long-term.
Protocol
IV NAD+ infusion (100–500mg) for rapid repletion — typically a series of 3–5 sessions. Oral NMN (500mg/day) or NR (300–500mg/day) for maintenance. Physician orders based on biological age gap, insulin resistance markers, or longevity-track protocol. Introduced alongside Epitalon at month 4 for patients with significant biological age delta.
Not a peptide — a coenzyme. Included here as a core WellSpry longevity protocol. Longevity + Metabolic Panel (launching soon) will include HbA1c, HOMA-IR, and homocysteine — the primary NAD+ indication and outcome markers.
Recommended Test
Longevity + Metabolic Panel (coming soon) — now: GLP-1 Panel + Testosterone & Hormone · $169 / $349 combo
AST · ALT · BUN · hs-CRP · Lipids · Albumin
How It Works
WellSpry peptide prescribing
01
Test
Your 100+ biomarker panel and gut score create the clinical documentation.
02
Interpret
Your physician reviews the results and identifies which peptides are warranted — if any.
03
Prescribe
Patient-specific prescription sent to our 503A licensed pharmacy network (Belmar Pharma).
04
Fill
You fill the prescription directly. WellSpry never touches the compound.
This is not a questionnaire. This is not a research chemical vendor. This is a board-certified physician reading your actual biomarkers and writing a patient-specific prescription through a licensed 503A compounding pharmacy. Biomarker-driven. Physician-authorised. Fully documented.